



Investor News 2005

Recent news and the news contents can be obtained from our website www.investor.bayer.com

- December 20, 2005 **New treatment for advanced renal cell carcinoma: Anticancer drug Nexavar[®] granted U.S. approval**
- Approval faster than expected
- Major milestone for Bayer oncology franchise
- Shipment to pharmacies within the next 24 hours
- December 14, 2005 **Dr. Wolfgang Plischke appointed to the Bayer Management Board**
- Dr. Gunnar Riemann to head the Pharmaceuticals Division
- Peter Nicklin to take charge of the Animal Health Division
- December 13, 2005 **47th Annual Meeting of the American Society of Hematology: Novel, oral Factor Xa inhibitor (BAY 59-7939): Positive results of Phase II once-daily study presented**
10 mg once-daily dose to be studied in Phase III clinical trials for prevention of venous thromboembolism (VTE)
- December 12, 2005 **Landmark Study Demonstrates Benefits of Prophylactic Treatment Regimen in Hemophilia A**
Results from Multi-year Clinical Trial Shows Improved Joint Outcomes in Young Children Using Kogenate[®] FS
- December 08, 2005 **Bayer Launches Phase III Clinical Study of Trasylo[®] in Elective Spinal Fusion Surgery**
Study Examines Effects of Trasylo[®] in Reducing Bleeding and Need for Blood Transfusions for Spinal Fusion Patients
- December 08, 2005 **Investor conference in London on research and development: Wenning: "We have great confidence for the future"**
- Phase III study with Nexavar[®] to treat lung cancer
- Oral thrombosis drug entering Phase III with once-daily dose
- Sales forecasts raised for Kogenate[®] and Trasylo[®]
- New CropScience active ingredients have sales potential of EUR 2 billion
- MaterialScience a global trendsetter in plant capacity and process efficiency
- December 06, 2005 **Bayer creates a provision in the amount of 275 million euros for civil antitrust actions**
- November 30, 2005 **Avelox[®] Approved in US to Treat Complicated Intra-abdominal Infections**
Once-a-day Dosage Offers Effective and Convenient Treatment Option
- November 28, 2005 **Bayer HealthCare Receives FDA Approval for Kogenate[®] FS with BIO-SET[®]**
Innovative reconstitution system will offer safety and simplicity for people living with hemophilia A
- November 16, 2005 **Bayer MaterialScience increases prices for HDI and HDI-based aliphatic isocyanates**

- November 09, 2005 Fall Financial News Conference of Bayer AG
Bayer boosts third-quarter earnings: operating result doubled
 - Third-quarter sales up 19.1 percent to EUR 6,531 million
 - Strong gains by all subgroups
 - Group net income up from EUR 52 million to EUR 493 million
 - Guidance raised again: full-year underlying EBIT expected to increase by about 50 percent
- November 03, 2005 **Bayer HealthCare: Majority holding in anti-infectives research acquired by Santo Holding AG**
 Jobs in Wuppertal to remain / closing expected in 1st quarter of 2006
- November 03, 2005 **Investigator Presents Update on Phase III Sorafenib Trial in Patients with Advanced Kidney Cancer**
- October 26, 2005 Cooperation for Factor Xa-Inhibitor, BAY 59-7939:
Bayer HealthCare and Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson Company, Announce Collaborative Development and License Agreement for Antithrombosis Drug
 - U.S. marketing rights to Ortho-McNeil for cardiology, primary care and hospital segments
 - Co-promotion agreement for marketing of Ortho-McNeil drug Elmiron® by Bayer HealthCare to the urology audience
- October 21, 2005 **Bayer wins approval for Avelox® (Moxifloxacin) in Japan**
 - Shionogi & Co. Ltd. has exclusive marketing rights
 - Japan is the world's second largest pharmaceutical market
- October 20, 2005 **Window is opening for polycarbonate automobile window glazing**
 US Department of Transportation confirms that Exatec® 900 window glazing system can be used in the USA
- October 06, 2005 **Bayer ceases bidding for Boots OTC business**
- September 30, 2005 Dr. Derek W. Gilroy receives International Aspirin® Award
New mechanism of action of Aspirin discovered
 The active ingredient of Aspirin® stimulates the production of nitric oxide, thereby inhibiting inflammation
- September 19, 2005 **Trasylo! (Aprotinin Injection) Reduced Bleeding and Transfusion Requirements in Patients on Clopidogrel who Required Coronary Artery Bypass Graft (CABG) Surgery**
 New study addresses critical days prior to CABG surgery when stopping antiplatelet therapy may delay operation and expose patients to risk of cardiac events
- September 14, 2005 **Bayer and Onyx Announce FDA Acceptance of New Drug Application for Sorafenib for Individuals with Advanced Renal Cell Carcinoma**
 Priority Review Designation Granted
- September 12, 2005 **Bayer and Onyx Announce European Marketing Submission for Sorafenib**
 European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma
- September 05, 2005 "Analyst and Investor Days 2005" in Lyon:
Bayer CropScience: Sales of new products should rise to € 2 billion
 Company counting on its first-class product pipeline
- August 10, 2005 Bayer interim report:
Dynamic sales and earnings growth continues in the second quarter
 - Sales rise 20 percent to over EUR 7 billion
 - EBIT before special items up 39 percent
 - Group net income almost tripled to EUR 406 million
 - Significant increase in guidance for 2005 sales and underlying EBIT
 - About 40 percent growth in underlying EBIT predicted for 2005
- August 08, 2005 XXth Congress of the International Society on Thrombosis & Haemostasis (ISTH):
Promising Safety and Efficacy Results of BAY 59-7939 Phase II Studies Pave the Way for Phase III Clinical Program to Begin this Year

July 19, 2005 Enormous interest from investors
Bayer successfully completes refinancing
 EUR 1.3 billion hybrid bond issued / Bayer repurchases bonds with a face value of around EUR 860 million

July 19, 2005 **Two Phase-II studies indicate that oral BAY 59-7939 is safe and effective in preventing venous thromboembolism**

July 11, 2005 **Bayer and Onyx Complete Filing of New Drug Application for Sorafenib for Individuals with Advanced Renal Cell Carcinoma**

July 07, 2005 **Bayer repurchases part of Eurobond issue and launches new hybrid bonds**

July 01, 2005 Increased transparency in drug development:
Bayer HealthCare posts information on clinical trials on the Internet

June 30, 2005 Bayer presses ahead with investment projects in China:
First stage of major polycarbonate project inaugurated
 - Go-ahead for construction of a world-scale MDI plant with a capacity of 350,000 tons/year
 - Global MDI capacity to be increased to 1.3 million tons/year

June 29, 2005 Innovative liposome technology
Bayer Completes Investigational New Drug filing with FDA For Longer-Acting Kogenate[®] Product
 Company ready to begin Phase I clinical trials with hemophilia A patients

June 06, 2005 **Bayer sells mandatory convertible bond back to Lanxess**

May 24, 2005 **Bayer MaterialScience closes TDI Facility at New Martinsville**

May 14, 2005 **Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) for Individuals with Advanced Renal Cell Carcinoma**
 Treatment Protocol has been Reviewed by FDA

May 14, 2005 **Sorafenib (BAY 43-9006) Doubles Progression-Free Survival in Phase III Kidney Cancer Trial**
 Independent Assessment Shows Median Progression-Free Survival of 24 Weeks

May 13, 2005 **Bayer and Onyx Initiate Phase III Metastatic Melanoma Trial Administering Sorafenib (BAY 43-9006) in Combination with Chemotherapy**

May 12, 2005 Bayer CropScience plans further profitable growth:
Sales of new active ingredients to reach EUR 1 billion, EBITDA margin to improve to 25 % by 2006
 Innovative products to offer new solutions for farmers, drive company growth

May 10, 2005 Existing plants expanded and investment in China accelerated:
Bayer MaterialScience significantly increases Makrolon[®] production
 1,000,000 tons capacity expected by end of 2005, further expansion on the horizon

May 10, 2005 Bayer Group interim report:
Sales and earnings advance strongly in first quarter
 - 2005 guidance for Bayer HealthCare increased
 - Full-year Group forecast confirmed

May 04, 2005 **Sorafenib (BAY 43-9006) Accepted into FDA Pilot 1 Program**

April 29, 2005 Opening up a new dimension
Bayer MaterialScience to participate in the development of holographic storage media
 - Cooperation agreement signed with high-tech US company
 - Aim is for storage media with a capacity of up to 1.6 terabytes
 - Highly promising market for Bayer MaterialScience's polymer raw materials

April 29, 2005 Werner Wenning at the Annual Stockholders' Meeting in Cologne:
Bayer's earnings advance strongly in first quarter
 - Underlying EBIT from continuing operations up by 50.1 % to EUR 1,142 million
 - Full-year 2005 forecasts confirmed
 - Wenning calls for R&D commitment by politicians

April 19, 2005 **Bayer CropScience announces supply agreement for Imidacloprid with Cheminova**

April 19, 2005 **Bayer CropScience and Makhteshim Agan sign multi-year non-exclusive supply agreement for Imidacloprid**

April 18, 2005 **Bayer and Onyx Unblind Patients In Ongoing Sorafenib Phase III Clinical Trial In Advanced Renal Cell Carcinoma**
Independent Committee Endorses Company Decision To Offer All Patients Active Drug

April 11, 2005 **Bayer Initiates Phase III Clinical Study of Trasylol® Therapy During Primary Total Hip Replacement Surgery**
Study Examines the Effects of Trasylol in Reducing Blood Loss and the Need for Transfusion

April 01, 2005 **Bayer completes transaction involving plasma business**
Kogenate® product line remains in Bayer HealthCare portfolio

March 21, 2005 **BAY 43-9006 Shown to Delay Disease Progression in Phase III Study in Advanced Kidney Cancer Patients**
- Study met surrogate endpoint
- Bayer and Onyx plan to prepare a NDA for possible accelerated approval in the US

March 15, 2005 Werner Wenning at the Spring Financial News Conference on March 15:
Bayer expects considerable growth in sales and earnings from continuing operations in 2005
- Adjusted EBIT from continuing operations to increase by some 20 percent
- Encouraging figures for January and February
- All subgroups contribute to successful performance in 2004
- Strategic realignment of the Bayer Group completed

March 08, 2005 **Bayer and Onyx Announce Initiation of Phase III Clinical Trial of BAY 43-9006 in Patients with Advanced Primary Liver Cancer**

March 02, 2005 Provisional figures for fiscal 2004:
Bayer significantly improves both sales and earnings
- Currency- and portfolio-adjusted sales rise by 9 percent
- EBIT before special items up 53 percent to EUR 2.2 billion
- Management Board proposes dividend of EUR 0.55 per share for 2004

February 23, 2005 **Advisory Panel Discussion points to Aleve®**
Members of FDA Committees Support Safety of Naproxen, Active Ingredient in Aleve®

February 04, 2005 **Bayer CropScience, Max Planck Society and Monsanto Company resolve Agrobacterium patent dispute**

February 03, 2005 Bayer CropScience CEO Prof. Dr. Friedrich Berschauer in Brazil:
Bayer CropScience intends to further expand its market leadership position in Latin America
Sales in Latin America rise 32 % in the first nine months of 2004

January 28, 2005 Entry in the Bayer AG commercial register:
Lanxess spin-off accomplished

January 18, 2005 **Lanxess Listing Memorandum to be published on January 19**

January 13, 2005 **U.S. EPA grants approval for use of Bayer CropScience's Stratego fungicide to control Asian soybean rust**

January 10, 2005 **GSK's Levitra Co-Promotion Rights Transferred Back to Bayer in Most Major Markets Outside the U.S.**

January 01, 2005 Deal successfully closed and Roche Consumer Health business now integrated
Bayer Consumer Care Operates combined Business January 1
Division ranks among the top three OTC players – Supradyn®, Redoxon®, Bepanthen®, and Rennie® are now in the Bayer family of brands